Halozyme Therapeutics valuation
Valuation
The P/E ratio is 38.3. The average price target of 9 analysts is $108.78.
Data as of November 17, 2026
Halozyme Therapeutics compared with similar companies
Halozyme Therapeutics's P/E (trailing 12 months): 38.3, in line with the median of a group of 7 similar companies (38.3).
| Metric | Halozyme Therapeutics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 38.3 | 38.3 | 19.1 – 69.1 | Middle |
| Forward P/E | 9.19 | 15.5 | 9.15 – 25.0 | Middle |
| EV/EBITDA | 11.6 | 17.0 | 13.4 – 27.9 | Low |
| Price/book | 87.5 | 7.54 | 4.09 – 14.6 | High |
| Price/sales | 7.52 | 7.23 | 4.95 – 9.17 | Middle |
| Gross margin | 76.3% | 77.3% | 71.2% – 91.5% | Middle |
| Operating margin | 56.8% | 19.5% | -5.3% – 29.2% | High |
| Net margin | 24.9% | 4.4% | -5.7% – 30.2% | Middle |
| ROE | 173.7% | 8.3% | -4.2% – 88.3% | High |
| Debt/equity | 15.2 | 0.30 | 0.06 – 0.75 | High |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Halozyme Therapeutics: valuation over time
On the latest fiscal year's earnings (2025), Halozyme Therapeutics's P/E today is 37.4, above the median of its last 7 fiscal years (26.3; between 13.9 and 46.9 from 2017 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $67.30 | $2.56 | 26.3 |
| 2024 | $47.81 | $3.43 | 13.9 |
| 2023 | $36.96 | $2.10 | 17.6 |
| 2022 | $56.90 | $1.44 | 39.5 |
| 2021 | $40.21 | $2.74 | 14.7 |
| 2020 | $42.71 | $0.91 | 46.9 |
| 2019 | $17.73 | -$0.50 | — |
| 2018 | $14.63 | -$0.56 | — |
| 2017 | $20.26 | $0.45 | 45.0 |
| 2016 | $9.88 | -$0.81 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $14.67B
- Enterprise value
- $13.21B
- EV/revenue
- 7.33
Profitability and growth
- ROA
- 25.5%
- ROIC
- 28.2%
- Revenue growth (year over year)
- 47.7%
- Earnings growth (year over year)
- 42.9%
Financial health
- Total cash
- $1.07B
- Total debt
- $3.28B
- Current ratio
- 2.71
- Quick ratio
- 1.99
- Altman Z-Score
- 3.45
- Piotroski F-Score
- 6.00
Analysts and estimates
- Average price target
- $108.78
- High price target
- $130.00
- Low price target
- $78.00
- Analysts with a price target
- 9
- Consensus
- Buy
Shares and trading
- Beta
- 0.88
- Average volume
- 2.29M
- Shares outstanding
- 114.01M
- Float
- 112.7M
- Institutional ownership
- 100.0%
- Insider ownership
- 1.1%
- Short interest (% of float)
- 12.1%
- Short ratio (days)
- 6.19
